Patient-Derived Xenograft (PDX) Tumor Models

• One of thelargestcollectionofAsiaprevalent tumortypesintheworld» Liver-284» Lung-196» Colorectal-105» Gastric-93» Esophageal-90» Cholangiocarinoma-41

• DrugresistantPDX• Recurrent/metastasisPDX

• 400PDXsin-lifeforrapidstudyonset• End-userfriendlydatabase• Effectiveprojectmanagement• AAALACaccreditedSPFfacility

• Clinicalinformation» Clinicalclassification» Pathology» Treatmenthistory

• PDXgrowthcharacteristics» Growthcurves» SoCtreatment

• >500PDXgenomicprofiled» Affymetrixmicroarray» Whole-exomesequencing» SNP6.0array» RNAseq

> 1000 PDX Panel

Unique Com

positi

on

Quality Service

Well Annotated

The largest collection of Asia prevalent tumor types with genomic profiling

Clinical diagnosis ProfiledPancreatic cancer 54 57

Kidney cancer 8 9Head & Neck cancer 14 27

Breast cancer 16 17Melanoma 11 14

Liposarcoma 3 10GIST 7 13

Nasopharyngeal carcinoma 2 4Ovarian cancer 1 2

Gallbladder cancer 7 9Glioma 4 4

Lymphoma 19 20Endometrial cancer 4 4

• > 1000 PDX models• The largest collection of Asia prevalent PDX models• > 500 PDX models with genetic profiling• Searchable online database with mobile APP

Clinical diagnosis Profiled Established

Lung cancerNSCLC

ACD 34 38

SCC 108 117

Large cell 3 3

SCLC 4 4

Others 20 34

Gastric cancer 77 93

HCC 139 284

Colorectal cancer (105) 105 7

Esophageal cancer 63 90

Cholangiocarcinoma 36 41

Oncology & Immunology

Cervical cancer 2 4 Sarcoma 1 2

Established

CH CO ES GIST HCC LP LC ME PanC GC Total AMP 1 2 1 9 6 1 16 36ERBB2 2 1 9 12FGFR1 4 4FGFR2 1 1KIT 1 1KRAS 1 6 7MET 1 8 1 1 11Fusion 6 6ALK 4 4FGFR2 1 1ROS1 1 1Mutation 2 62 3 3 5 1 31 8 48 13 176AKT1 1 1BRAF 3 1 3 1 8EGFR 1 4 1 6ERBB2 1 1FGFR3 1 4 5HRAS 1 1JAK1 1 1KIT 3 4 7KRAS 2 41 2 12 42 9 108NRAS 1 1 2PIK3CA* 14 3 1 1 10 4 3 36Total 3 64 4 3 14 1 43 8 49 29 218

PDX with oncogene amplification, mutation & Fusions

NOTE: 1) Gene amplification was defined as average CNV>5 from SNP6.0 array data2) Only reported oncogenic/hotspot mutations were counted . PIK3CA mutation usually co-occur with other events (KRAS mutation et al.)

Integrated online database for PDX, CDX & Syngeneic tumor models with mobile App

http://onco.wuxiapptec.com

ON

C20

1603

F3

onco.wuxiapptec.comEmail: info_onco@wuxiapptec.com

1200

3000

2800

250

600

Oncology & Immunology